Key result
Transfemoral access for TAVR in patients with peripheral artery disease was associated with similar in-hospital mortality compared to transapical access (4.8% vs 5.1%; OR 0.95, 95% CI 0.74-1.21).
Why the study?
There is a paucity of data regarding outcomes with transfemoral versus transapical access for TAVR in patients with peripheral artery disease.
Does transfemoral access compared to transapical access reduce in-hospital mortality in patients with peripheral artery disease undergoing TAVR?
Observational (n=6,692)
Yes
Does transfemoral access compared to transapical access reduce in-hospital mortality in patients with peripheral artery disease undergoing TAVR?
Odds Ratio: 0.95 (95% CI 0.74–1.21)
Absolute Event Rate: 4.8% vs 5.1%
In patients with peripheral artery disease undergoing TAVR, transfemoral access has similar in-hospital mortality to transapical access but is associated with fewer systemic complications and shorter hospital stays, despite higher rates of vascular complications and pacemaker insertion.
Similar in-hospital mortality with TF-TAVR versus TA-TAVR should not yet change practice; leaves open optimal access route selection in randomized trials.
BACKGROUND: There is a paucity of data regarding outcomes with transfemoral (TF) versus transapical (TA) access for transcatheter aortic valve replacement (TAVR) in patients with peripheral artery disease (PAD). METHODS: We queried the national inpatient sample database (NIS) (2012-2013) to identify patients with PAD who underwent TAVR. We conducted a propensity matching analysis using 25 clinical variables to compare TF-TAVR versus TA-TAVR. The main outcome was in-hospital mortality. RESULTS: The analysis included 22,349 patients who underwent TAVR, among those 6692 (29.9%) had PAD. In the matched cohort, in-hospital mortality was similar between TF-TAVR and TA-TAVR groups (4.8% vs. 5.1%, OR 0.95; 95%CI 0.74-1.21). TF-TAVR was associated with lower rates of cardiogenic shock (OR 0.64; 95%CI 0.50-0.82), use of mechanical circulatory support (OR 0.56; 95%CI 0.42-0.75), acute kidney injury (OR 0.76; 95%CI 0.67-0.86), hemodialysis (OR 0.51; 95%CI 0.36-0.71), major bleeding (OR 0.72; 95%CI 0.64-0.80), blood transfusion (OR 0.65; 95%CI 0.58-0.73), discharge to a skilled nursing facility (OR 0.61; 95%CI 0.54-0.68) as well as shorter length of hospital stay (8.13 ± 6.76 vs. 10.11 ± 7.80 days) compared with TA-TAVR. However, TF-TAVR was associated with higher rate of vascular complications (11.7% vs. 3.7%, OR 3.40; 95%CI 2.63-4.38), complete heart block (OR 1.52; 95%CI 1.23-1.87), and pacemaker insertion (OR = 1.58; 95%CI: 1.28-1.94). There was no difference between both groups in the rate of cerebrovascular accidents (OR 1.26; 95%CI 0.93-1.72). CONCLUSION: In this observational analysis from a large national database, there was no difference in in-hospital mortality between TF-TAVR and TA-TAVR among patients with PAD. Further studies are encouraged to identify the optimal access for TAVR in patients with PAD.
No takes yet. Share an insight, caveat, or question.
Elbadawi et al. (2019) conducted an observational in Peripheral arterial disease undergoing TAVR (n=6,692). Transfemoral access for TAVR vs. Transapical access for TAVR was evaluated on In-hospital mortality (OR 0.95, 95% CI 0.74-1.21). Transfemoral access for TAVR in patients with peripheral artery disease was associated with similar in-hospital mortality compared to transapical access (4.8% vs 5.1%; OR 0.95, 95% CI 0.74-1.21).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: